NCT06678412

Brief Summary

Self-report scales used in the assessment of cognitive functions can serve as an initial screening tool for the general population, aside from specific neuropsychiatric tests, which are more costly and time-consuming. This study is designed to examine the validity and reliability of the Turkish version of the Cognitive Functioning Self-Assessment Scale (CFSS). Permission for the study has been obtained from the developer of the scale, Dr. Maria Antonietta Annunziata. The Turkish translation of the scale will be made, and approval will be obtained from the original author for the final version. Subsequently, the Turkish version of the CFSS, the Hospital Anxiety and Depression Scale, and the Cognitive Failures Questionnaire will be administered to participants. Surveys will be completed either online via Google Forms or in written form. To assess the reliability of the scale, the Turkish version of the CFSS will be re-administered to the same participants 7-14 days later.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
180

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 5, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 7, 2024

Completed
13 days until next milestone

Study Start

First participant enrolled

November 20, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 20, 2025

Completed
11 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2025

Completed
Last Updated

March 10, 2025

Status Verified

March 1, 2025

Enrollment Period

3 months

First QC Date

November 5, 2024

Last Update Submit

March 5, 2025

Conditions

Keywords

cognitive functionself-assessmentpsychometrics

Outcome Measures

Primary Outcomes (3)

  • Cognitive Functioning Self-Assessment Scale (Turkish Vesion)

    The "Cognitive Functioning Self-Assessment Scale" developed by Annunziata et al. in 2016, consists of 18 questions aimed at assessing cognitive function areas such as attention, memory, problem-solving, temporal-spatial orientation, and dual-task performance. Scoring is done on a 5-point Likert scale, ranging from 1 to 5. Higher scores on the scale indicate an increase in subjective cognitive complaints.

    Baseline and 7-14 days after

  • Hospital Anxiety and Depression Scale (HADS)

    The HADS was developed by Zigmond and Snaith in 1983. The HADS consists of a total of 14 items, including 7 items for anxiety and 7 items for depression. The items are scored between 0-3 points on a 4-point Likert-type scale according to how the individual felt in the previous week. The scores that can be obtained from anxiety and depression subscales vary between 0-21. The Turkish validity and reliability study of the scale was conducted by Aydemir et al. in 1997. High scores obtained from the scale indicate increased mood disorder.

    Baseline

  • Cognitive Failures Questionnaire (CFQ)

    The BDI is a self-report scale developed by Broadbent et al. in 1982 to assess cognitive failures that occur in daily life. Errors in perception, memory and motor functions are assessed with 25 questions. Each question is scored from 0 (never) to 4 (very often). The total score that can be obtained from the scale ranges from 0-100. Higher scores indicate an increased level of cognitive failure and worse cognitive status. The Turkish validity and reliability study of the scale was conducted by Ekici et al. in 2016.

    Baseline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Healthy individuals over 18 years old

You may qualify if:

  • Individuals over 18 years old

You may not qualify if:

  • Taking antidepressants
  • Having a neurological or psychiatric disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kutahya Health Sciences University

Kütahya, 43100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

November 5, 2024

First Posted

November 7, 2024

Study Start

November 20, 2024

Primary Completion

February 20, 2025

Study Completion

March 3, 2025

Last Updated

March 10, 2025

Record last verified: 2025-03

Locations